Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

218.04 -10.16 (-4.45%)
Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
These S&P500 stocks that are showing activity before the opening bell on Thursday.
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
Global Growth Hits the Brakes: A Mixed Economic Picture Emerges for 2025 and Beyond
The global economy is bracing for a significant slowdown, with leading financial institutions projecting a challenging landscape for 2025 and the years to follow. A confluence of escalating trade... 
Via MarketMinute
Topics Economy Supply Chain World Trade
1 Reason Every Investor Should Know About AbbVie (ABBV)
This company's past ability to extend patent-protected market exclusivity for its drugs bodes well for new investors. 
Via The Motley Fool
Topics Intellectual Property
This Is What Whales Are Betting On AbbVie
 
Via Benzinga
AbbVie Seeks To Expand Psychiatry Pipeline By Acquiring Gilgamesh’s Lead Candidate For Up To $1.2B
Via Stocktwits
AbbVie’s Investigational Drug For Alopecia Yields Positive Outcomes In Late-Stage Study
Via Stocktwits
3 Dividend Stocks to Double Up on Right Now
Investors can feel good about upping their bets on these great dividend stocks. 
Via The Motley Fool
Topics Energy Intellectual Property
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
Topics Intellectual Property
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
There is more to like than the dividend with these companies. 
Via The Motley Fool
Topics Intellectual Property
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years
 
Via Benzinga
1 Safe-and-Steady Stock with Promising Prospects and 2 Facing Headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Is Healthcare Setting Up to Be a Quiet Leader Into Year-End?
Over $11 billion flowed into the popular healthcare sector ETF XLV in Q2 alone, suggesting smart money is positioning for a potential rebound. 
Via MarketBeat
Topics ETFs
5 High-Yield Dividend Stocks I Plan on Holding for the Next 10 Years or Longer
Selling these dividend stocks isn't on my radar at all. 
Via The Motley Fool
Topics Energy Intellectual Property
The Smartest Dividend Stocks to Buy With $500 Right Now
You won't need a lot of money up front to begin raking in dividends from these great stocks. 
Via The Motley Fool
Topics World Trade
Deal Dispatch: PepsiCo, Sycamore, Dr. Phil, SSENSE, Bain's Chindata Lead M&A, Bankruptcy Moves
Deal activity this week included PepsiCo, Sycamore and Bain while the bankruptcy front included SSENSE and Dr. Phil. 
Via Benzinga
Topics Bankruptcy
2 Reasons to Watch ABBV and 1 to Stay Cautious
AbbVie currently trades at $207.60 per share and has shown little upside over the past six months, posting a small loss of 0.7%. The stock also fell short of the S&P 500’s 9.2% gain during that... 
Via StockStory
Topics Stocks Supply Chain
As the Market Rotates, This Healthcare ETF Is Leading the Way
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure. 
Via MarketBeat
Topics ETFs
AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment
Via Benzinga
3 Top Stocks to Build Your Portfolio Around
These great businesses can help patient investors beat the market. 
Via The Motley Fool
3 Unstoppable Dividend Stocks to Buy Right Now
Investors will get great dividends and more with these stocks. 
Via The Motley Fool
Topics World Trade
Tesla's Quality Score Tumbles, While Taiwan Semiconductor's Growth Rating Soars
Daily stock price moves often dominate headlines, but shifts in fundamental ranking scores can reveal a deeper story. This week, Benzinga's proprietary Growth data highlighted major swings among... 
Via Benzinga
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever.
Sit back and let the income roll in with this great exchange-traded fund. 
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
1 Profitable Stock Worth Investigating and 2 That Underwhelm
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Jackson Hole Symposium 2025: The Fed Signals a Pivotal Shift Towards Easing
The annual Jackson Hole Economic Policy Symposium, a highly anticipated gathering of global central bankers, finance ministers, and leading economists, is currently underway in Wyoming. This year's... 
Via MarketMinute
Topics Bonds Credit Cards Economy
All Eyes on Jackson Hole: Will Jerome Powell Signal Imminent Rate Cuts?
Global financial markets are on tenterhooks, fixated on the highly anticipated speech by Federal Reserve Chair Jerome Powell at the annual Jackson Hole Economic Symposium. Investors are keenly awaiting... 
Via MarketMinute
Topics Bonds Credit Cards Economy
A Congress Member Bought Up To $1.17M In AbbVie Stock: Here's What You Need To Know
 
Via Benzinga
AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib
AbbVie's Rinvoq Phase 3 trial showed strong efficacy in severe alopecia areata, with many patients achieving significant scalp hair regrowth by week 24. 
Via Benzinga
2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer
These high-yield dividend stocks are built to last. 
Via The Motley Fool
Topics Intellectual Property
Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers. 
Via StockStory
Topics Artificial Intelligence
Jackson Hole Symposium Looms: Why Investors Are Holding Their Breath for Powell's Remarks
The financial world is abuzz with anticipation as the annual Jackson Hole Economic Symposium draws near, an exclusive gathering hosted by the Federal Reserve Bank of Kansas City in the serene mountains... 
Via MarketMinute
Topics Bonds Climate Change Economy
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.